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Abstract
Objectives: To investigate the role of CGS21680, a selective adenosine A2A receptor agonist, on a bile-duct-ligated cirrhotic liver
resection model in rats.
Methods: Male Wistar rats were allotted into 3 groups (n = 7 per time-point): the control group, the bile duct ligation + CGS21680
group (BDL + CGS), and the bile duct ligation group (BDL). Biliary cirrhosis had been previously induced by ligature of the common
bile duct in the BDL + CGS and BDL groups. After 2 weeks, the animals underwent partial hepatectomy (50%). The BDL + CGS group
received a single dose of CGS21680 15 minutes prior to hepatectomy. Blood samples were collected and analyzed.
Results: Aspartate transaminase levels were found to be lower in the control vs BDL groups (1, 3, and 24 h) (P < 0.01) and the BDL
+ CGS (1 and 3 hours) (P < 0.01) and BDL + CGS vs BDL (24 hours) (P < 0.05) groups. Hepatic flow was measured and BDL showed
significantly lower values at the 3, 24, and 168 h time-points compared to the control (P < 0.01) and BDL + CGS groups (P < 0.05 at 3
and 168 hours; P < 0.01 at 24 h). O2C velocity was reduced in the BDL compared to the control group (P < 0.001 at 3 hours; P < 0.01 at
24 and 168 hours) and the BDL + CGS group (P < 0.01 at 24 hours). Interleukin-6 levels were abrogated in the BDL + CGS (P < 0.05) and
control (P < 0.01) groups versus BDL. Histone-bound low-molecular-weight DNA fragments in the BDL + CGS (P < 0.01) and control
(P < 0.05) groups were low compared to the BDL group.
Conclusions: Administration of CGS21680, an adenosine receptor agonist, after the resection of bile-duct-ligated cirrhotic livers led
to improved liver function, regeneration, and microcirculation.
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1. Background
Liver cirrhosis (LC) is a deleterious clinical condition
that leads to irreversible damage to the organ. LC distorts
the normal architecture of the liver and is characterized by
fibrosis, hepatic injury, and nodular regeneration. These
changes lead to impaired function and ultimately to organ
failure or liver cancer. The causes of LC can be infectious
(e.g. viral hepatitis B, C, and D), genetic disease (e.g. Wil-
son’s disease, cystic fibrosis, hemochromatosis), drugs and
poisons (e.g. alcohol, methotrexate), or other conditions
such as chronic biliary obstruction.
According to the world health organization and the
European association for the study of the liver, 1.8% of all
deaths in Europe are due to LC, at a rate of 170,000 deaths
annually (1). Hepatocellular carcinoma (HCC) is one of
the leading causes of death worldwide, and LC is one of
the major risk factors for its development (2). Approxi-
mately 85% - 95% of HCCs occur in patients with LC (3, 4).
HCC is associated with intrahepatic inflammation, oxida-
tive DNA damage, and oxidative stress (5). Chronic inflam-
mation is known to be the root cause for many diseases due
to increased proinflammatory cytokines (6). Studies have
shown that agonists for G-protein coupled receptors, such
as cell-surface adenosine purinergic receptors, upregulate
the immunosuppressive cyclic AMP in immune cells. Ohta
and Sitkovsky showed that attenuation of inflammation
and tissue damage in vivo was due to the non-redundant
role of A2A adenosine receptors (A2ARs) (6).
A2ARs are ubiquitously present in almost all organs;
however, they are highly expressed in the brain and play
an important role in the regulation of glutamic acid and
the release of dopamine. These features make it an ideal
therapeutic target for treating certain conditions, includ-
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ing Parkinson’s disease, depression, and pain (7-9). Evi-
dence suggests that they are also expressed in the liver,
especially in Kupffer cells, hepatocytes, and stellate cells
(10-12). Mice devoid of A2AR have shown elevated levels of
proinflammatory cytokines, in line with elevated biochem-
ical parameters and the histological data.
Surgical interventions, such as liver transplantation,
partial hepatectomy, and tumor resection, can lead to
blood loss and ischemia-reperfusion injury (IRI) of the
liver. Portal triad clamping, also called Pringle’s maneu-
ver, is an effective technique to control blood loss during
liver resection (13). However, IRI following Pringle’s ma-
neuver may lead to hepatic dysfunction and liver insuf-
ficiency (14). IRI triggers a cascade of inflammatory re-
sponses in damaged tissues. Extensive research has shown
that A2AR activation promotes hepatic ischemic precondi-
tioning both in vivo and in vitro (15-18). A recent study by
Dal Ponte et al. showed that ischemic postconditioning us-
ing CGS21680, an A2AR agonist, has protective effects on
hepatocytes (17).
2. Objectives
Considering all of the beneficial effects of A2ARs in pre-
vious studies, we used CGS21680, a selective A2AR agonist,
in the present study. We hypothesized that the adminis-
tration of CGS21680 in cirrhotic livers induced by bile duct
ligation would ameliorate reperfusion-associated injury in
an experimental rat model and may improve regeneration.
3. Methods
All experiments were conducted in accordance with
German federal law and European directive 2010/63/EU
on the protection of animals used for scientific proce-
dures. Our experiments were also in compliance with
the guide for the care and use of laboratory animals
(8th edition, NIH publication, 2011, USA). The govern-
mental care and use committee (LANUV), Recklinghausen,
NRW, Germany, granted official permission. Male Wistar
rats (Charles River GmbH, Sulzfeld, Germany) weighing
250 - 350 g were used in this study. The animals were
housed under SPF-conditions according to FELASA guide-
lines (www.felasa.org) in a temperature- and humidity-
controlled environment (certified according to DIN-ISO
9001/2008) with a 12 hour light/dark cycle. They were al-
lowed food (standard rat diet, Sniff-Spezialdiäten GmbH,
Soest, Germany) and water ad libitum.
3.1. Experimental Groups and Operative Procedures
The animals were randomly assigned to the following 3
groups: the control group, with no bile duct ligation (n = 7);
the bile duct ligation group that received CGS21680 treat-
ment (BDL + CGS group) (n = 7); and the bile duct ligation
group that did not receive CGS treatment (BDL group) (n =
7). These groups were further divided into 4 subgroups ac-
cording to varying time-points of observation time (OT): 1,
3, 24, and 168 h OT after liver resection (n = 7 at each time-
point in each group). General anesthesia was induced by
inhalation of 5 vol% of isoflurane (Abbot GmbH and Co. KG,
Wiesbaden, Germany) and 5 L/min of oxygen. Thereafter,
the anesthesia concentration was reduced and maintained
at 2 vol% with 2 L/min of oxygen. Cefuroxime sodium (16
mg/kg per 24 hours) (Cefuroxim Fresenius; Fresenius Kabi
Deutschland GmbH, Bad Hamburg, Germany), a preopera-
tive prophylactic antibiotic, was injected subcutaneously.
As perioperative analgesia, buprenorphine (0.1 mg/kg per
24 hours) (Temgesic; Essex Pharma, München, Germany)
was injected for 24 hours or up to 3 days after surgery.
Hamza et al. previously described the following surgi-
cal procedure (3). A midline laparotomy was performed to
expose the abdomen. In the BDL + CGS and BDL groups,
we induced secondary biliary liver cirrhosis by ligating the
bile duct. Next, through a small incision, the duodenum
was reached in order to place the common bile duct under
tension. After isolating the common bile duct, the duct was
ligated twice using PDS-6.0 (Ethicon, Johnson and Johnson,
Lenneke Marelaan, Belgium) and then dissected. The ab-
dominal wall was closed in 2 layers, the first with contin-
uous sutures, then the skin with interrupted sutures. The
animals were then placed in a special intensive care unit
(Vetario; Brinsea products Ltd., North Somerset, United
Kingdom) for recovery, with warmed air (30 - 35°C) for at
least 15 min. After 2 weeks, the animals underwent par-
tial liver resection of 50% of the liver mass (left liver lobe
[LLL], anterior caudate [AC] lobe, and posterior caudate
[PC] lobe). In the BDL + CGS group, the animals were treated
15 minutes before the resection with a single dose of a se-
lective A2AR agonist, CGS21680 (Sigma Chemicals, Deisen-
hofen, Germany), at a dose of 10 µg/kg body weight intra-
venously via the penile vein. All surgical procedures were
performed under aseptic conditions. In the control group,
the same surgical procedure was performed without prior
BDL and CGS administration.
3.2. Enzyme Release/Hepatocellular Damage
As a general parameter of hepatocellular damage, as-
partate transaminase (AST) release was measured at 1, 3, 24,
and 168 hours. Serum samples were collected after liver re-
section and assessed by a standard enzymatic method us-
ing a Vitros 250 analyzer (Ortho Clinical Diagnostics, NJ,
USA).
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3.3. Microcirculation of the Liver
We used a laser Doppler flowmeter combined with
a near-infrared spectrophotometry device (O2C: Oxygen
to See; LEA Medizintechnik GmbH, Giessen, Germany) to
measure the microcirculation of the liver. Portal venous
flow (PVF) was measured with a transit-time perivascular
flowmeter (T403; Transonic Systems, Inc., Ithaca, NY, USA)
using a Transonic flow probe (MA2PSB; Transonic Systems,
Inc.).
3.4. In situ Cell Death Detection
Apoptosis was quantified at 24 hours using an enzyme-
linked immunosorbent assay (ELISA) kit (Roche Molec-
ular Biochemicals, Mannheim, Germany) according to
the manufacturer’s instructions. The assay detected low-
molecular-weight histone-bound DNA fragments in the tis-
sue lysate. Results were expressed as arbitrary units (AU).
3.5. Proinflammatory Cytokines
Serum levels of interleukin-6 (IL-6) 3 hours after reper-
fusion were measured with rat ELISA kits (R&D Systems,
Minneapolis, MN) according to the manufacturer’s in-
structions.
3.6. Histopathology
Liver tissue sections were collected after resection and
the samples were stored in 100 g/L of paraformaldehyde for
24 hours (fixation). Later, the samples were transferred to
40 g/L of paraformaldehyde for storage. The tissue samples
were then embedded, sectioned, and stained using hema-
toxylin and eosin (H&E). Examinations of all slides were
performed using a Leica DM 2500 optic microscope (Wet-
zlar, Germany) under ×400 magnification. An in-house
pathologist who was blinded to the experimental condi-
tions scored the lesions on a scale of 1-5 (1 = no or negligible
changes, lesions affecting 0% - 10% of the field; 2 = mild, le-
sions affecting 10% - 30% of the field; 3 = mild to moderate,
lesions affecting 30% - 60% of the field; 4 = moderate to se-
vere, lesions affecting 60% - 80% of the field; and 5 = severe;
lesions affecting > 80% of the field).
3.7. TUNEL Staining
Histological evaluation for apoptosis was done by in
situ labeling for DNA fragmentation using terminal de-
oxynucleotidyl transferase-mediated deoxy-UTP nick-end
labeling (TUNEL). The TUNEL test was performed using
the standard protocol and a commercial kit (Boehringer
Mannheim, Mannheim, Germany) provided by the man-
ufacturer. The counting of TUNEL-positive cells was per-
formed with ImageJ software (version 1.48a for Mac OSX,
National Institutes of Health, MD, USA), in 5 random fields.
The results are expressed as percentage of positive cells.
3.8. Ki-67 Staining
As described previously by Hamza et al. (3), tissue sec-
tions were subjected to immunohistochemical staining
using the avidin-biotin complex method and diaminoben-
zidine. The antibodies used in this study were monoclonal
mouse Ki-67 (MIB5, 1:10; DACO, Glostrup, Denmark) for as-
sessing the cell proliferation rate.
3.9. Statistical Analysis
The results are expressed as mean± standard error of
mean (mean ± SEM) for each group. The statistical analy-
ses between the groups were performed using either one-
way or two-way analysis of variance (ANOVA) and Tukey’s
multiple comparison test. Values of < 0.05 were consid-
ered to be statistically significant. All statistical calcula-
tions were made using Prism 6.0f for Mac OS X (GraphPad
Software Inc., San Diego, CA, USA).
4. Results
AST release was measured as a general parameter of
hepatocellular damage. The 24 hours post-resection time-
point showed significantly higher levels of AST in the BDL
group (281±43 IU/L) compared to the BDL + CGS group (193
± 25 IU/L). The control group showed significantly lower
AST (126 ± 18 IU/L) compared to the BDL group; however,
there was no significant difference recorded between the
control and BDL + CGS groups. At the end of 168 hours,
there were no significant differences recorded between the
three groups: control (40± 11 IU/L), BDL (70± 15 IU/L), and
BDL + CGS (72± 13 IU/L) (Figure 1).



















Results are expressed as mean±SEM; two-way ANOVA, Tukey’s multiple comparison
test. a, P < 0.01 vs. BDL and BDL + CGS (1 hour, 3hours); b, P < 0.0001 vs. BDL; c, P <
0.05 vs. BDL + CGS (n = 7).
O2C flow was measured to evaluate microcirculation
in the liver. O2C flow values were significantly lower at 3
h in the BDL group (122 ± 7 AU) compared to the control
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(175 ± 9 AU) and BDL + CGS (167 ±8 AU) groups. Similarly,
the BDL group showed significantly lower values at the 24
hours and 168 hours time-points (137 ± 13 AU and 123 ± 8
AU, respectively) compared to the control group (182 ± 6
AU and 175 ± 8 AU, respectively) and the BDL + CGS group
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Figure 2. A, O2C flow measurement in the liver at 1, 3, 24, and 168 hours. Results are
expressed as mean± SEM; two-way ANOVA, Tukey’s multiple comparison test. a, P <
0.01 vs. control (3 hours, 24 hours, 168 hours); b, P < 0.05 vs. BDL; c, P < 0.01 vs. BDL
(n = 7). B, O2C velocity measurement in the liver at the four time-points. Results are
expressed as mean± SEM; two-way ANOVA, Tukey’s multiple comparison test. a, P <
0.001 vs. control; b, P < 0.01 vs. control; c, P < 0.01 vs. BDL (n = 7).
Similar to O2C flow, O2C velocity was recorded at all
time-points to assess the volume of blood flow in the or-
gan. The BDL group (18±0 AU) showed significantly lower
values at 24 hours compared to the control group (22± 0
AU) and the BDL + CGS group (22± 1 AU). Interestingly, the
BDL + CGS group showed values similar to those of the con-
trol group (Figure 2B).
PVF was measured at all time-points, and levels were
significantly different at the 24 hours time-point between
the control group (24 ± 2 mL/min) and the BDL group (13
± 2 mL/min). However, there were no significant differ-
ences between the BDL + CGS group (20 ± 3 mL/min) and
the other two (Figure 3).
IL-6 levels are known to be upregulated in tissue dam-

















Figure 3. PVF after liver resection at the four time-points. Results are expressed as
mean± SEM; two-way ANOVA, Tukey’s multiple comparison test. a, P < 0.01 vs. con-
trol (n = 7).
assess the extent of this damage. The BDL group showed
significantly higher levels of IL-6 (512.6 ± 83.99 pg/mL)
compared to the control (197.4 ± 8.80 pg/mL) and BDL +
























Figure4. Release of IL-6 in the serum at the 3 hours time-point. Results are expressed
as mean± SEM; one-way ANOVA, Tukey’s multiple comparison test. a, P < 0.01 vs.
BDL; b, P < 0.05 vs. BDL (n = 7).
To assess the extent of apoptosis, we measured histone-
bound DNA fragments in the tissue lysate at the 24 hours
time-point. The BDL group showed significantly higher lev-
els of these fragments (0.081± 0.011 AU) in comparison to
the control (0.045 ± 0.006 AU) and BDL + CGS (0.027 ±
0.005 AU) groups (Figure 5).
Histological analysis and scoring revealed that the con-
trol group was the least affected, with a mean score of 1
(negligible damage), while the BDL + CGS group showed
a mean score of 2.2 (mild damage) and the BDL group
showed a mean score of 4.1 (moderate to severe damage)
(Figure 6). Quantification of TUNEL-positive cells showed
4 Hepat Mon. 2016; 16(8):e36821.































Figure 5. Measurement of low-molecular-weight histone-bound DNA fragments at
the 24-hours time-point to assess the extent of apoptosis. Results are expressed as
mean± SEM; one-way ANOVA, Tukey’s multiple comparison test. a, P < 0.05 vs. BDL;
b, P < 0.01 vs. BDL (n = 7).
significantly higher numbers in the BDL group (2.9 ±
0.82 AU) compared to the control (0.04 ± 0.04 AU) and
BDL+CGS (0.4 ± 0.24 AU) groups (Table 1). Hepatocyte
proliferation was evaluated with immunohistochemistry
showing Ki-67-positive nuclei. The BDL + CGS group (9.3±
3.2 AU) showed significantly higher positively-stained nu-
clei compared to the BDL group (1.0± 0.5 AU) (Table 1).
Values are expressed as mean± SEM; one-way ANOVA.
Tukey’s multiple comparison test: n = 5; a,b P < 0.01 vs BDL;
c P < 0.05 vs BDL. BDL: bile duct ligation, BDL + CGS: bile
duct ligation + CGS21680.
5. Discussion
Liver cirrhosis is a major contributing factor in hepato-
cellular carcinoma. Mokdad et al., in their systematic anal-
ysis, showed the extent of mortality due to LC in 187 coun-
tries between the years 1980 and 2010. Their astounding re-
sults showed that LC caused more than one million deaths
worldwide in the year 2010 (19).
Resection or transplant surgery are still the most ac-
cepted treatments for LC and HCC. Surgical interventions
carry a higher risk of blood loss; hence, surgeons per-
form Pringle’s maneuver for safe resection of the cirrhotic
liver (13). However, Pringle’s maneuver is associated with
IRI, which can cause many complications, including liver
failure (20). Research has shown that IRI is one of the
major complications of liver surgery, with exponentially
increased postoperative morbidity and mortality (14, 21).
Apart from the abovementioned complications, IRI is also
the most common reason for early graft dysfunction after
liver transplantation (22, 23).
A variety of preventive measures have been recom-
mended to minimize IRI; for example, Peralta et al. showed
that ischemic preconditioning could be an option (20).
Alchera et al. suggested that A2AR agonists minimize IRI
in the liver (24). A2ARs are known to play a very impor-
tant role in hepatic IRI (6). Increased cellular consumption
of adenosine triphosphate leads to accumulation of extra-
cellular adenosine, which is believed to exert cytoprotec-
tive effects on ischemic tissues (25). Research shows that
adenosine may inhibit the synthesis of inflammatory pa-
rameters via A2 receptor stimulation, or by averting the
downregulation of endothelial nitric oxide synthase dur-
ing IRI (18, 26) Peralta et al. reported that increased adeno-
sine activates A2ARs, leading to increased nitric oxide con-
centration and thereby blocking hepatic injury during IRI
(18). Many studies have suggested that the use of A2AR ag-
onists, such as CGS21680, minimizes hepatic IRI (17, 25, 27).
In the present study, we wanted to test A2AR stim-
ulation in a more clinically relevant model; therefore,
we induced LC by ligating the common bile duct. We
then evaluated the effect of CGS21680 after cirrhotic liver
resection. The main aim was to elucidate the role of
CGS21680 in the amelioration of IRI-related (microcircula-
tory/microvasculature) damage.
Previous studies have shown that stimulation of A2ARs
promotes hepatic preconditioning, first in in vitro and
then in in vivo experiments (17, 18, 28). In a small-for-size
liver transplantation model, Tang et al. showed that acti-
vation of A2ARs by administration of CGS21680 improved
liver function, decreased portal hypertension, inhibited
apoptosis, and decreased neutrophil infiltration (29). Al-
though A2ARs are distributed ubiquitously, their levels are
highest in the spleen, thymus, and leucocytes compared
to the liver, where levels are rather low (29, 30). Never-
theless, CGS21680 is known to increase hepatocyte viabil-
ity under hypoxic conditions (15). Research has shown
that CGS21680 has protective effects on hepatocytes, such
as vasodilation, decreased inflammation, and suppression
of apoptosis (29). In our study, we measured AST levels
as a general parameter for hepatic function, and noticed
that the enzyme levels were significantly abrogated at the
24 hours time-point in the presence of CGS21680. These
findings proved the protective effects exerted by CGS21680,
which in turn stimulates the A2ARs. Our results are in line
with the results reported by Tang et al. in their study involv-
ing CGS21680 in small-for-size liver transplantation (29).
Liver grafts are susceptible to IRI damage during surgical
procedures, such as liver transplantation or resection. Pre-
treatment of rats with CGS21680 is also known to increase
tolerance against IR-related damage (24, 28).
CGS21680 is a highly selective drug for A2ARs, and var-
ious researchers have already established the omnipres-
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Figure 6. Histopathological Findings
H&E staining of liver tissue 24 hours after resection: control (A), BDL + CGS (B), BDL (C); TUNEL staining for apoptotic/necrotic cells, control (D), BDL + CGS (E), BDL (F); im-
munohistochemical analysis of hepatocyte proliferation with Ki-67 positive nuclei: control (G), BDL + CGS (H), BDL (I). BDL: bile duct ligation; BDL + CGS: bile duct ligation +
CGS21680.× 400.
Table 1. Quantification of TUNEL- and Ki-67-Positive Cells
Control BDL + CGS BDL P Value
TUNEL (AU) 0.04± 0.04a 0.4± 0.24b 2.9± 0.82 < 0.01
Ki-67 (AU) 4.4± 1.2 9.3± 3.2c 1.0± 0.5 < 0.05
ence of these receptors (16, 31). However, the most interest-
ing feature of A2ARs are their presence in the vasculature,
specifically in the smooth muscle and endothelium. A2ARs
are known to mediate adenosine-induced vasodilatation
in the hepatic arterial bed (HA) (32). Mathie et al. showed
that CGS21680 exhibited 3 times greater potency in induc-
ing HA vasodilatation compared to adenosine (32). The va-
sodilative properties of A2ARs are well established in the
aorta, coronary artery, and mesenteric artery (33). In the
present study, PVF showed no significant differences; how-
ever, we could demonstrate significantly higher levels of
hepatic flow and velocity in the presence of CGS21680. In
this way, we could clearly prove that A2AR stimulation with
CGS21680 caused vasodilatation in comparison to the BDL
group. Furthermore, significantly higher velocity in the
CGS21680-treated group validates the vasodilative proper-
ties on A2ARs. Nonetheless, the molecular mechanisms be-
hind these results need further investigation.
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Liver sinusoidal endothelial cells are known to pro-
duce IL-6, a pro-inflammatory cytokine. IL-6 attenuates
apoptosis and helps in the regeneration of hepatocytes
(34). Inflammation and tissue damage lead to increased
levels of IL-6; concurrently, an increased level of IL-6 in-
duces insulin resistance and liver inflammation, especially
in patients with non-alcoholic fatty liver disease (34). In
this study, we noticed the attenuation of IL-6 release in the
presence of CGS21680, the absence of which was correlated
to significantly higher levels of IL-6. These results were in
line with results previously published by Tang et al. (29).
Interestingly, the decreased levels of IL-6 in the BDL + CGS
group also showed significantly lower levels of apoptosis.
The favorable results of cell death detection and decreased
occurrence of TUNEL-positive cells in the BDL + CGS group
contribute to the fact that CGS21680 attenuates apoptosis
(29).
Histopathological analyses showed moderate to se-
vere damage of liver tissue in the BDL group, with semi-
quantitative scores showing an increased level of biliary
proliferation in multiple liver lobules. Further analysis of
the slides also revealed infiltration of inflammatory cells in
certain areas, along with necrotic/apoptotic cells. Minor et
al. showed that stimulation of A2ARs better protected pre-
damaged cold-stored liver grafts, and there was much less
IRI-related damage (35). In another similar study, Ben-Ari
et al. showed that rats treated with CGS21680 showed sig-
nificantly lower levels of apoptotic cells; they also showed
that the histological sections revealed a high level of aci-
dophilic bodies (25). Simultaneously, proliferative activity
was assessed by the number of Ki-67-positive nuclei ente-
rocytes. The end result showed a significantly lower level
of Ki-67-positive cells in the BDL group. These results were
in line with the previously obtained histopathological re-
sults.
In summary, after 50% liver resection, cirrhotic livers
treated with CGS21680 showed significant improvements
in their microvasculature and structure. A2AR stimula-
tion provided robust protection against inflammation and
apoptosis. However, further confirmatory studies with
larger sample sizes are needed in the future. Our prelim-
inary experimental data clearly showed attenuation of AST
levels, improved flow and velocity, better-preserved tissue
structure, and improved regeneration upon activation of
A2ARs. These promising results could promote CGS21680,
an A2AR agonist, as a therapeutic option for liver cirrhosis.
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